伊马替尼辅助治疗胃肠间质瘤所面临的问题  

The current situation and problems of adjuvant imatinib for gastrointestinal stromal tumors(GIST)

作　　者：马良[1] 钟鉴宏[1] 黎乐群[1] 

机构地区：[1]广西医科大学附属肿瘤医院肝胆外科,广西南宁530021

出　　处：《现代肿瘤医学》2011年第10期2101-2104,共4页Journal of Modern Oncology

摘　　要：保证切缘无癌的切除手术是局限性胃肠间质瘤(GIST)的主要治疗方法,然而,术后复发率高,5年生存率很低。传统的放疗及化疗对GIST几乎无效;伊马替尼治疗不可切除/转移/复发GIST疗效显著,使得伊马替尼辅助治疗的应用日益受到重视。然而,目前伊马替尼辅助治疗的应用尚存在很多疑问。本文就其应用的现状及面临的问题做一综述。Resection with complete cancer-free margin is the curative treatment of localised,primary gastrointestinal stromal tumors.But the recurrence rate is high and the 5-year survival rate is very low.Conventional radiotherapy and chemotherapy are almost ineffective against this tumor,however,the treatment with imatinib is encouraging for advanced GIST with longer progression-free survival.So,the role of adjuvant imatinib treatment in GIST receives more and more attention.But there are still many questions about the application of adjuvant imtinib,such as the most suitable patients,optimal duration of treatment and dose.

关 键 词：胃肠间质瘤 GIST 辅助治疗 最佳人群 生存率 

分 类 号：R730.51[医药卫生—肿瘤]